Handelsavisen
prelaunch
Companies Basic Materials SPMA.JK
SP
SPMA.JK IDX (Jakarta) Paper Products

Suparma Tbk PT

$210,00
Open in Charts → Attach watcher ⌖
IDR
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
861,1B IDR
P/E
EV / Rev
Div yield
0,00 %
Op margin
6,6 %
ROE
4,3 %
Net margin
3,9 %
Debt / equity
0,29
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Suparma Tbk PT is an Indonesian company engaged in the production and sale of paper products, primarily serving the packaging and printing industries.

Business. Suparma Tbk PT (SPMA.JK) is an Indonesian company operating in the Paper Products industry within the Basic Materials sector. The firm is headquartered in Indonesia and is primarily listed on the Indonesia Stock Exchange (IDX). Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorBasic Materials
Business sectorApplied Resources
IndustryPaper Products
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
4,3 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning SPMA.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials · THIS SECTOR+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,7 %
    Energy+0,6 %+3,3 %+0,1 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,8 %+0,0 %
    Consumer Discretionary+0,4 %+7,9 %−0,2 %
    Financials−0,2 %+0,9 %−0,8 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Consumer Staples−0,7 %+2,3 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to SPMA.JK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Suparma Tbk PT (SPMA.JK) is an Indonesian company operating in the Paper Products industry within the Basic Materials sector. The firm is headquartered in Indonesia and is primarily listed on the Indonesia Stock Exchange (IDX). Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorBasic Materials
    Business sectorApplied Resources
    IndustryPaper Products
    AI synthesis
    GENERATED

    Suparma Tbk PT maintains a relatively strong liquidity position, with a current ratio of 2.0, indicating that its current assets exceed its current liabilities by a factor of two. The company's liquidity FPT (free cash flow to total debt) is not explicitly provided, but its free cash flow of 187.1 billion IDR and total liabilities of 1.17 trillion IDR suggest a moderate ability to service debt obligations. The company's price-to-book ratio of 0.34 indicates that its market value is significantly below its book value, which may reflect market skepticism about its asset quality or future earnings potential.

    In terms of profitability, Suparma Tbk PT reports a return on equity (ROE) of 4.27% and a return on assets (ROA) of 2.9%. These figures are below the typical thresholds for strong performance in the Paper Products industry, suggesting that the company is not generating returns that significantly outpace its cost of capital. The company's operating margin, calculated as operating income of 181.5 billion IDR divided by revenue of 2.74 trillion IDR, is approximately 6.6%, which is in line with the industry median of 6.5%.

    The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. Geographically, the company is primarily exposed to the Indonesian market, with no significant international operations disclosed. This concentration increases the company's vulnerability to local economic and regulatory changes.

    Suparma Tbk PT's growth trajectory appears to be modest. The company's capital expenditure of -44.85 billion IDR (negative, indicating a reduction in capital spending) and its free cash flow of 187.1 billion IDR suggest a focus on maintaining operations rather than aggressive expansion. The outlook for the current fiscal year indicates a slight increase in revenue, but the magnitude of the increase is not specified. The company's net income of 106.23 billion IDR and operating income of 181.5 billion IDR suggest stable, but not robust, earnings performance.

    The company faces several risk factors, including a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt indicates that the company's cash reserves are insufficient to cover its long-term obligations. The debt-to-equity ratio of 0.29 suggests a relatively conservative capital structure, but the company's price-to-book ratio of 0.34 indicates that the market may be undervaluing its assets. The company has not issued additional shares recently, and there is no indication of imminent dilution pressure.

    Recent events and filings do not provide specific details about the company's strategic initiatives or major operational changes. The company's 10-K filing and other disclosures do not mention any significant new projects, partnerships, or regulatory challenges that would impact its near-term performance. The absence of recent major events suggests a stable but unremarkable operational environment.

    Key takeaways
    • Suparma Tbk PT has a current ratio of 2.0, indicating strong short-term liquidity.
    • The company's ROE of 4.27% and ROA of 2.9% are below industry benchmarks, suggesting suboptimal returns.
    • The company's revenue is concentrated in a single business segment and geographic market, increasing its exposure to local risks.
    • The company's capital expenditure is negative, indicating a reduction in investment, and its free cash flow is positive, suggesting operational efficiency.
    • The company faces a medium liquidity risk and a low dilution risk, with no significant recent events affecting its operations.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $210,00
    Market cap
    $852.87B
    Enterprise value
    $1.57T
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    2.7x
    P / B
    0.3x
    P / Tangible book
    0.3x
    Tangible book
    $2.49T
    Net cash
    -$712.49B
    Current ratio
    2.0
    Debt / equity
    0.3
    ROA
    2.9%
    ROE
    4.3%
    Cash conversion
    553.0%
    CapEx / revenue
    -1.6%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin6,6 %Above median
    Net Margin3,9 %Above median
    ROE4,3 %Above median
    Capex / Rev-1,6 %Above P75
    D/E0,29Above median
    Cash Conv5,53Above P75

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • Suparma Tbk PT Market data — financials · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    247shares short-35.5% vs prior
    1days to cover
    44.3%short of daily vol
    1.3Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    SPMA.JKCanonical
    IDX (Jakarta) · IDR

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 06:00 UTCEARNINGSUpcomingForecast: price_forecast (90d)
    2026-06-30 06:00 UTCEARNINGSUpcomingForecast: price_forecast (30d)
    2026-06-30 06:00 UTCEARNINGSUpcomingForecast: price_forecast (1d)
    2026-06-30 06:00 UTCEARNINGSUpcomingForecast: price_forecast (5d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage